

# Geoffrey R Oxnard

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/11493316/geoffrey-r-oxnard-publications-by-year.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

138  
papers

12,250  
citations

49  
h-index

110  
g-index

157  
ext. papers

15,007  
ext. citations

9.3  
avg, IF

6.27  
L-index

#	Paper	IF	Citations
138	Early Readout on Overall Survival of Patients With Melanoma Treated With Immunotherapy Using a Novel Imaging Analysis.. <i>JAMA Oncology</i> , <b>2022</b> ,	13.4	3
137	An imaging signature to predict outcome in metastatic colorectal cancer using routine computed tomography scans.. <i>European Journal of Cancer</i> , <b>2022</b> , 161, 138-147	7.5	1
136	Tumor mutational burden as a predictive biomarker for immune checkpoint inhibitor versus taxane chemotherapy benefit in metastatic castration-resistant prostate cancer: A real-world biomarker study.. <i>Journal of Clinical Oncology</i> , <b>2022</b> , 40, 162-162	2.2	
135	Tumor mutational burden as a predictive biomarker for immune checkpoint inhibitor versus chemotherapy benefit in first-line metastatic urothelial carcinoma: A real-world study.. <i>Journal of Clinical Oncology</i> , <b>2022</b> , 40, 547-547	2.2	0
134	Molecular residual disease (MRD) detection with a tissue comprehensive genomic profiling (CGP)-informed personalized monitoring assay: An exploratory analysis of the IMvigor-010 observation arm.. <i>Journal of Clinical Oncology</i> , <b>2022</b> , 40, 448-448	2.2	0
133	Detection of EGFR mutations in non-small cell lung cancer by droplet digital PCR.. <i>PLoS ONE</i> , <b>2022</b> , 17, e0264201	3.7	0
132	Genomic evolution from hormonal therapies and suitability of prostate cancer diagnostic specimens for metastatic prostate cancer (mPC) genomic stratification.. <i>Journal of Clinical Oncology</i> , <b>2022</b> , 40, 143-143	2.2	0
131	Comparative Effectiveness of Immune Checkpoint Inhibitors vs Chemotherapy by Tumor Mutational Burden in Metastatic Castration-Resistant Prostate Cancer.. <i>JAMA Network Open</i> , <b>2022</b> , 5, e225394	10.4	1
130	Prevalence of UV Mutational Signatures Among Cutaneous Primary Tumors.. <i>JAMA Network Open</i> , <b>2022</b> , 5, e223833	10.4	0
129	Predictive Genomic Biomarkers of Hormonal Therapy Versus Chemotherapy Benefit in Metastatic Castration-resistant Prostate Cancer. <i>European Urology</i> , <b>2021</b> , 81, 37-37	10.2	3
128	SPACEWALK: A Remote Participation Study of ALK Resistance Leveraging Plasma Cell-Free DNA Genotyping. <i>JTO Clinical and Research Reports</i> , <b>2021</b> , 2, 100151	1.4	0
127	Genomic Evolution in a Patient With Lung Adenocarcinoma With a Germline T790M Mutation. <i>JTO Clinical and Research Reports</i> , <b>2021</b> , 2, 100146	1.4	
126	Savolitinib ± Osimertinib in Japanese Patients with Advanced Solid Malignancies or EGFRm NSCLC: Ph1b TATTON Part C. <i>Targeted Oncology</i> , <b>2021</b> , 16, 339-355	5	0
125	ERBB2 copy number (CN) as a quantitative biomarker for real-world (RW) outcomes to anti-HER2 therapy in advanced gastroesophageal adenocarcinoma (adv GEA).. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 4045-4045	2.2	1
124	High Sensitivity of Plasma Cell-Free DNA Genotyping in Cases With Evidence of Adequate Tumor Content. <i>JCO Precision Oncology</i> , <b>2021</b> , 5,	3.6	1
123	Real-world (rw) clinical outcomes on alpelisib (ALP) in patients (pts) with breast cancer (BC) and PIK3CA mutations (PIK3CAm).. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 1068-1068	2.2	0
122	Genomic immunotherapy (IO) biomarkers detected on comprehensive genomic profiling (CGP) of tissue and circulating tumor DNA (ctDNA).. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 2541-2541	2.2	3

121	Integration of immunotherapy into adjuvant therapy for resected non-small-cell lung cancer: ALCHEMIST chemo-IO (ACCIO). <i>Immunotherapy</i> , <b>2021</b> , 13, 727-734	3.8	2
120	Intracranial Efficacy of Selpercatinib in Fusion-Positive Non-Small Cell Lung Cancers on the LIBRETTO-001 Trial. <i>Clinical Cancer Research</i> , <b>2021</b> , 27, 4160-4167	12.9	12
119	Prognostic Significance of Blood-Based Multi-cancer Detection in Plasma Cell-Free DNA. <i>Clinical Cancer Research</i> , <b>2021</b> , 27, 4221-4229	12.9	18
118	The PATHFINDER Study: Assessment of the Implementation of an Investigational Multi-Cancer Early Detection Test into Clinical Practice. <i>Cancers</i> , <b>2021</b> , 13,	6.6	11
117	The Genomics of Young Lung Cancer: Comprehensive Tissue Genomic Analysis in Patients Under 40 With Lung Cancer. <i>JTO Clinical and Research Reports</i> , <b>2021</b> , 2, 100194	1.4	0
116	Genomic and pathological heterogeneity in clinically diagnosed small cell lung cancer in never/light smokers identifies therapeutically targetable alterations. <i>Molecular Oncology</i> , <b>2021</b> , 15, 27-42	7.9	6
115	Comparing RECIST 1.1 and iRECIST in advanced melanoma patients treated with pembrolizumab in a phase II clinical trial. <i>European Radiology</i> , <b>2021</b> , 31, 1853-1862	8	5
114	Overcoming MET-Dependent Resistance to Selective RET Inhibition in Patients with RET Fusion-Positive Lung Cancer by Combining Selpercatinib with Crizotinib. <i>Clinical Cancer Research</i> , <b>2021</b> , 27, 34-42	12.9	32
113	Genetic Ancestry Contributes to Somatic Mutations in Lung Cancers from Admixed Latin American Populations. <i>Cancer Discovery</i> , <b>2021</b> , 11, 591-598	24.4	20
112	Circulating tumor DNA in advanced solid tumors: Clinical relevance and future directions. <i>Ca-A Cancer Journal for Clinicians</i> , <b>2021</b> , 71, 176-190	220.7	31
111	Strategies for the successful implementation of plasma-based NSCLC genotyping in clinical practice. <i>Nature Reviews Clinical Oncology</i> , <b>2021</b> , 18, 56-62	19.4	35
110	Plasma ctDNA Response Is an Early Marker of Treatment Effect in Advanced NSCLC. <i>JCO Precision Oncology</i> , <b>2021</b> , 5,	3.6	4
109	Genomic Analysis of Circulating Tumor DNA in 3,334 Patients with Advanced Prostate Cancer Identifies Targetable BRCA Alterations and AR Resistance Mechanisms. <i>Clinical Cancer Research</i> , <b>2021</b> , 27, 3094-3105	12.9	26
108	Genomic analysis of circulating tumor DNA in 3,334 patients with advanced prostate cancer to identify targetable BRCA alterations and AR resistance mechanisms.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 25-25	2.2	1
107	Contrasting genomic profiles from metastatic sites, primary tumors, and liquid biopsies of advanced prostate cancer. <i>Cancer</i> , <b>2021</b> , 127, 4557-4564	6.4	0
106	Oncogenic switch and single-agent MET inhibitor sensitivity in a subset of -mutant lung cancer. <i>Science Translational Medicine</i> , <b>2021</b> , 13, eabb3738	17.5	0
105	Turnaround Time of Plasma Next-Generation Sequencing in Thoracic Oncology Patients: A Quality Improvement Analysis. <i>JCO Precision Oncology</i> , <b>2020</b> , 4,	3.6	4
104	Identification of a RAS-activating Fusion in an Exceptional Responder to Sunitinib with Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 4072-4079	12.9	2

103	Traditional Diagnostics versus Disruptive Technology: The Role of the Pathologist in the Era of Liquid Biopsy. <i>Cancer Research</i> , <b>2020</b> , 80, 3197-3199	10.1	5
102	Molecular Mechanisms of Acquired Resistance to MET Tyrosine Kinase Inhibitors in Patients with MET Exon 14-Mutant NSCLC. <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 2615-2625	12.9	60
101	Use of Patient-Derived Tumor Organotypic Spheroids to Identify Combination Therapies for Mutant Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 2393-2403	12.9	12
100	Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA. <i>Annals of Oncology</i> , <b>2020</b> , 31, 745-759	10.3	303
99	Circulating tumor DNA analysis in the era of precision oncology. <i>Oncotarget</i> , <b>2020</b> , 11, 188-211	3.3	24
98	Next-generation sequencing informs diagnosis and identifies unexpected therapeutic targets in lung squamous cell carcinomas. <i>Lung Cancer</i> , <b>2020</b> , 140, 35-41	5.9	12
97	Enhanced Detection of Treatment Effects on Metastatic Colorectal Cancer with Volumetric CT Measurements for Tumor Burden Growth Rate Evaluation. <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 6464-6474	12.9	2
96	Efficacy of Selpercatinib in Fusion-Positive Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , <b>2020</b> , 383, 813-824	59.2	194
95	Effective Cancer Genotyping-Many Means to One End. <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 4583-4585	12.9	9
94	Sensitivity of next-generation sequencing assays detecting oncogenic fusions in plasma cell-free DNA. <i>Lung Cancer</i> , <b>2019</b> , 134, 96-99	5.9	45
93	Monitoring Therapeutic Response and Resistance: Analysis of Circulating Tumor DNA in Patients With ALK+ Lung Cancer. <i>Journal of Thoracic Oncology</i> , <b>2019</b> , 14, 1901-1911	8.9	59
92	EGFR-Mutated Lung Cancers Resistant to Osimertinib through EGFR C797S Respond to First-Generation Reversible EGFR Inhibitors but Eventually Acquire EGFR T790M/C797S in Preclinical Models and Clinical Samples. <i>Journal of Thoracic Oncology</i> , <b>2019</b> , 14, 1995-2002	8.9	34
91	Genome-wide cell-free DNA (cfDNA) methylation signatures and effect on tissue of origin (TOO) performance.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 3049-3049	2.2	12
90	The Circulating Cell-free Genome Atlas (CCGA) Study: Follow-up (F/U) on non-cancer participants with cancer-like cell-free DNA signals.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 5574-5574	2.2	4
89	Does TMB Impact the Effectiveness of TKIs in -Mutant NSCLC?. <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 899-900	12.9	10
88	Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review. <i>Archives of Pathology and Laboratory Medicine</i> , <b>2018</b> , 142, 1242-1253	5	72
87	Monitoring of Response and Resistance in Plasma of EGFR-Mutant Lung Cancer Using Droplet Digital PCR. <i>Methods in Molecular Biology</i> , <b>2018</b> , 1768, 193-207	1.4	4
86	False-Positive Plasma Genotyping Due to Clonal Hematopoiesis. <i>Clinical Cancer Research</i> , <b>2018</b> , 24, 4437-4443	12.9	210

85	Assessment of Resistance Mechanisms and Clinical Implications in Patients With EGFR T790M-Positive Lung Cancer and Acquired Resistance to Osimertinib. <i>JAMA Oncology</i> , <b>2018</b> , 4, 1527-1534	13.4	342
84	Phase Ib Study of High-dose Intermittent Afatinib in Patients With Advanced Solid Tumors. <i>Clinical Lung Cancer</i> , <b>2018</b> , 19, e655-e665	4.9	4
83	Hereditary Lung Cancer Risk: Recent Discoveries and Implications for Genetic Counseling and Testing. <i>Current Genetic Medicine Reports</i> , <b>2018</b> , 6, 83-88	2.2	2
82	Liquid biopsy of fine-needle aspiration supernatant for lung cancer genotyping. <i>Lung Cancer</i> , <b>2018</b> , 122, 72-75	5.9	35
81	Prevalence of clonal hematopoiesis of indeterminate potential (CHIP) measured by an ultra-sensitive sequencing assay: Exploratory analysis of the Circulating Cancer Genome Atlas (CCGA) study.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 12003-12003	2.2	29
80	Detection and clearance of RET variants in plasma cell free DNA (cfDNA) from patients (pts) treated with LOXO-292.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 9048-9048	2.2	3
79	Refining the sensitivity of plasma cell-free DNA (cfDNA) genotyping by controlling for plasma tumor content.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 9071-9071	2.2	3
78	Vol-PACT: A Foundation for the NIH Public-Private Partnership That Supports Sharing of Clinical Trial Data for the Development of Improved Imaging Biomarkers in Oncology. <i>JCO Clinical Cancer Informatics</i> , <b>2018</b> , 2, 1-12	5.2	7
77	Precision Medicine in Non-Small Cell Lung Cancer: Current Standards in Pathology and Biomarker Interpretation. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , <b>2018</b> , 38, 708-715	7.1	14
76	Identification of Incidental Germline Mutations in Patients With Advanced Solid Tumors Who Underwent Cell-Free Circulating Tumor DNA Sequencing. <i>Journal of Clinical Oncology</i> , <b>2018</b> , JCO1800328	2.2	49
75	Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 1631-1641	2.2	448
74	EGFR Exon 20 Insertion Mutations Display Sensitivity to Hsp90 Inhibition in Preclinical Models and Lung Adenocarcinomas. <i>Clinical Cancer Research</i> , <b>2018</b> , 24, 6548-6555	12.9	31
73	Osimertinib for Previously Treated Patients With Advanced EGFR T790M Mutation-Positive NSCLC: Tolerability and Diagnostic Methods From an Expanded Access Program. <i>Oncology and Therapy</i> , <b>2018</b> , 6, 45-58	2.7	1
72	Targeted Therapy as an Alternative to Whole-Brain Radiotherapy in EGFR-Mutant or ALK-Positive Non-Small-Cell Lung Cancer With Brain Metastases. <i>JAMA Oncology</i> , <b>2017</b> , 3, 1274-1275	13.4	34
71	Application of Plasma Genotyping Technologies in Non-Small Cell Lung Cancer: A Practical Review. <i>Journal of Thoracic Oncology</i> , <b>2017</b> , 12, 1344-1356	8.9	67
70	Response Heterogeneity of EGFR and HER2 Exon 20 Insertions to Covalent EGFR and HER2 Inhibitors. <i>Cancer Research</i> , <b>2017</b> , 77, 2712-2721	10.1	81
69	Discrimination of Germline T790M Mutations in Plasma Cell-Free DNA Allows Study of Prevalence Across 31,414 Cancer Patients. <i>Clinical Cancer Research</i> , <b>2017</b> , 23, 7351-7359	12.9	52
68	A Phase I, Dose Escalation Study of Oral ASP8273 in Patients with Non-small Cell Lung Cancers with Epidermal Growth Factor Receptor Mutations. <i>Clinical Cancer Research</i> , <b>2017</b> , 23, 7467-7473	12.9	22

67	Genomic Analysis of Plasma Cell-Free DNA in Patients With Cancer. <i>JAMA Oncology</i> , <b>2017</b> , 3, 740-741	13.4	49
66	Bias-Corrected Targeted Next-Generation Sequencing for Rapid, Multiplexed Detection of Actionable Alterations in Cell-Free DNA from Advanced Lung Cancer Patients. <i>Clinical Cancer Research</i> , <b>2016</b> , 22, 915-22	12.9	177
65	Activity of erlotinib when dosed below the maximum tolerated dose for EGFR-mutant lung cancer: Implications for targeted therapy development. <i>Cancer</i> , <b>2016</b> , 122, 3456-3463	6.4	11
64	A Highly Sensitive and Quantitative Test Platform for Detection of NSCLC EGFR Mutations in Urine and Plasma. <i>Journal of Thoracic Oncology</i> , <b>2016</b> , 11, 1690-700	8.9	203
63	A Prospective Evaluation of Circulating Tumor Cells and Cell-Free DNA in EGFR-Mutant Non-Small Cell Lung Cancer Patients Treated with Erlotinib on a Phase II Trial. <i>Clinical Cancer Research</i> , <b>2016</b> , 22, 6010-6020	12.9	84
62	Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 3375-82	2.2	605
61	The cellular origins of drug resistance in cancer. <i>Nature Medicine</i> , <b>2016</b> , 22, 232-4	50.5	40
60	Response Rate as a Regulatory End Point in Single-Arm Studies of Advanced Solid Tumors. <i>JAMA Oncology</i> , <b>2016</b> , 2, 772-9	13.4	24
59	MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 721-30	2.2	383
58	Association Between Younger Age and Targetable Genomic Alterations and Prognosis in Non-Small-Cell Lung Cancer. <i>JAMA Oncology</i> , <b>2016</b> , 2, 313-20	13.4	106
57	Institutional implementation of clinical tumor profiling on an unselected cancer population. <i>JCI Insight</i> , <b>2016</b> , 1, e87062	9.9	245
56	Early Intervention in Lung Cancers With Rapid Plasma Genotyping for EGFR and KRAS Mutations-Reply. <i>JAMA Oncology</i> , <b>2016</b> , 2, 1096-7	13.4	10
55	Defining a Radiomic Response Phenotype: A Pilot Study using targeted therapy in NSCLC. <i>Scientific Reports</i> , <b>2016</b> , 6, 33860	4.9	128
54	Prospective Validation of Rapid Plasma Genotyping for the Detection of EGFR and KRAS Mutations in Advanced Lung Cancer. <i>JAMA Oncology</i> , <b>2016</b> , 2, 1014-22	13.4	412
53	Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung Cancer. <i>Cancer Discovery</i> , <b>2016</b> , 6, 1334-1341	24.4	94
52	Rociletinib in EGFR-mutated non-small-cell lung cancer. <i>New England Journal of Medicine</i> , <b>2015</b> , 372, 1700-9	59.2	524
51	Delay of treatment change after objective progression on first-line erlotinib in epidermal growth factor receptor-mutant lung cancer. <i>Cancer</i> , <b>2015</b> , 121, 2570-7	6.4	35
50	Enhanced ratio of signals enables digital mutation scanning for rare allele detection. <i>Journal of Molecular Diagnostics</i> , <b>2015</b> , 17, 284-92	5.1	23

49	Response to Crizotinib in a Patient With Lung Adenocarcinoma Harboring a MET Splice Site Mutation. <i>Clinical Lung Cancer</i> , <b>2015</b> , 16, e101-4	4.9	70
48	Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M. <i>Nature Medicine</i> , <b>2015</b> , 21, 560-2	50.5	1021
47	Immunohistochemical Loss of LKB1 Is a Biomarker for More Aggressive Biology in KRAS-Mutant Lung Adenocarcinoma. <i>Clinical Cancer Research</i> , <b>2015</b> , 21, 2851-60	12.9	72
46	Prognostic impact of KRAS mutation subtypes in 677 patients with metastatic lung adenocarcinomas. <i>Journal of Thoracic Oncology</i> , <b>2015</b> , 10, 431-7	8.9	73
45	Expression of PD-1 and Its Ligands, PD-L1 and PD-L2, in Smokers and Never Smokers with KRAS-Mutant Lung Cancer. <i>Journal of Thoracic Oncology</i> , <b>2015</b> , 10, 1726-35	8.9	155
44	Clinical Implications of Variant ALK FISH Rearrangement Patterns. <i>Journal of Thoracic Oncology</i> , <b>2015</b> , 10, 1648-52	8.9	44
43	Identification of Oncogenic and Drug-Sensitizing Mutations in the Extracellular Domain of FGFR2. <i>Cancer Research</i> , <b>2015</b> , 75, 3139-46	10.1	26
42	Commentary. <i>Clinical Chemistry</i> , <b>2015</b> , 61, 586-7	5.5	
41	ALCHEMIST Trials: A Golden Opportunity to Transform Outcomes in Early-Stage Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , <b>2015</b> , 21, 5439-44	12.9	76
40	Preliminary results of TATTON, a multi-arm phase Ib trial of AZD9291 combined with MEDI4736, AZD6094 or selumetinib in EGFR-mutant lung cancer.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 2509-2509	2.2	24
39	Activity of AUY922 in NSCLC patients with EGFR exon 20 insertions.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 8015-8015	2.2	10
38	Designing a definitive trial for adjuvant targeted therapy in genotype defined lung cancer: the ALCHEMIST trials. <i>Chinese Clinical Oncology</i> , <b>2015</b> , 4, 37	2.3	8
37	Management of acquired resistance to epidermal growth factor receptor kinase inhibitors in patients with advanced non-small cell lung cancer. <i>Cancer</i> , <b>2014</b> , 120, 2289-98	6.4	25
36	Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA. <i>Clinical Cancer Research</i> , <b>2014</b> , 20, 1698-1705	12.9	580
35	Realizing the potential of plasma genotyping in an age of genotype-directed therapies. <i>Journal of the National Cancer Institute</i> , <b>2014</b> , 106,	9.7	38
34	Dacomitinib as first-line treatment in patients with clinically or molecularly selected advanced non-small-cell lung cancer: a multicentre, open-label, phase 2 trial. <i>Lancet Oncology</i> , <b>2014</b> , 15, 1433-1441	21.7	92
33	Definitive primary therapy in patients presenting with oligometastatic non-small cell lung cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2014</b> , 89, 880-7	4	104
32	Implementation of clinical next-generation sequencing (NGS) of non-small cell lung cancer (NSCLC) to identify EGFR amplification as a potentially targetable oncogenic alteration.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 8090-8090	2.2	1

31	Prediction of lung cancer genotype noninvasively using droplet digital PCR (ddPCR) analysis of cell-free plasma DNA (cfDNA).. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 8059-8059	2.2	1
30	Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer. <i>Science Translational Medicine</i> , <b>2013</b> , 5, 216ra177	17.5	313
29	New targetable oncogenes in non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 1097-1042.	2.2	249
28	Acquired Resistance to Targeted Therapies in Advanced Non-Small Cell Lung Cancer: New Strategies and New Agents. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , <b>2013</b> , e272-e278	7.1	4
27	Chemotherapy with Erlotinib or chemotherapy alone in advanced non-small cell lung cancer with acquired resistance to EGFR tyrosine kinase inhibitors. <i>Oncologist</i> , <b>2013</b> , 18, 1214-20	5.7	108
26	Power in numbers: meta-analysis to identify inhibitor-sensitive tumor genotypes. <i>Clinical Cancer Research</i> , <b>2013</b> , 19, 1634-6	12.9	7
25	Natural history and molecular characteristics of lung cancers harboring EGFR exon 20 insertions. <i>Journal of Thoracic Oncology</i> , <b>2013</b> , 8, 179-84	8.9	182
24	Acquired resistance to targeted therapies in advanced non-small cell lung cancer: new strategies and new agents. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , <b>2013</b> ,	7.1	10
23	Screening for germline EGFR T790M mutations through lung cancer genotyping. <i>Journal of Thoracic Oncology</i> , <b>2012</b> , 7, 1049-52	8.9	92
22	Clarifying the spectrum of driver oncogene mutations in biomarker-verified squamous carcinoma of lung: lack of EGFR/KRAS and presence of PIK3CA/AKT1 mutations. <i>Clinical Cancer Research</i> , <b>2012</b> , 18, 1167-76	12.9	297
21	When progressive disease does not mean treatment failure: reconsidering the criteria for progression. <i>Journal of the National Cancer Institute</i> , <b>2012</b> , 104, 1534-41	9.7	96
20	EGFR exon 19 insertions: a new family of sensitizing EGFR mutations in lung adenocarcinoma. <i>Clinical Cancer Research</i> , <b>2012</b> , 18, 1790-7	12.9	115
19	Strategies for overcoming acquired resistance to epidermal growth factor receptor: targeted therapies in lung cancer. <i>Archives of Pathology and Laboratory Medicine</i> , <b>2012</b> , 136, 1205-9	5	14
18	Reply to E.M. Gilles. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 117-117	2.2	1
17	Delay of chemotherapy through use of post-progression erlotinib in patients with EGFR-mutant lung cancer.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 7547-7547	2.2	18
16	Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling. <i>Science Translational Medicine</i> , <b>2011</b> , 3, 90ra59	17.5	383
15	Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib: implications for clinical trial design. <i>Clinical Cancer Research</i> , <b>2011</b> , 17, 6298-303	12.9	330
14	Variability of lung tumor measurements on repeat computed tomography scans taken within 15 minutes. <i>Journal of Clinical Oncology</i> , <b>2011</b> , 29, 3114-9	2.2	110



13	Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay. <i>Clinical Cancer Research</i> , <b>2011</b> , 17, 1169-80	12.9	467
12	New strategies in overcoming acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer. <i>Clinical Cancer Research</i> , <b>2011</b> , 17, 5530-7	12.9	282
11	"Pulsatile" high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer. <i>Neuro-Oncology</i> , <b>2011</b> , 13, 1364-9	1	268
10	Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation. <i>Clinical Cancer Research</i> , <b>2011</b> , 17, 1616-22	12.9	470
9	Maintained sensitivity to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer recurring after adjuvant erlotinib or gefitinib. <i>Clinical Cancer Research</i> , <b>2011</b> , 17, 6322-8	12.9	42
8	A pilot study of volume measurement as a method of tumor response evaluation to aid biomarker development. <i>Clinical Cancer Research</i> , <b>2010</b> , 16, 4647-53	12.9	89
7	Use of erlotinib or gefitinib as initial therapy in advanced NSCLC. <i>Oncology</i> , <b>2010</b> , 24, 392-9	1.8	13
6	Non-small cell lung cancer in octogenarians: treatment practices and preferences. <i>Journal of Thoracic Oncology</i> , <b>2007</b> , 2, 1029-35	8.9	30
5	Modeling of mesothelioma growth demonstrates weaknesses of current response criteria. <i>Lung Cancer</i> , <b>2006</b> , 52, 141-8	5.9	50
4	The radiologic measurement of mesothelioma. <i>Hematology/Oncology Clinics of North America</i> , <b>2005</b> , 19, 1053-66, vi	3.1	2
3	Evaluation of semiautomated measurements of mesothelioma tumor thickness on CT scans. <i>Academic Radiology</i> , <b>2005</b> , 12, 1301-9	4.3	29
2	Radiologic Assessment of Mesothelioma <b>2005</b> , 433-453		1
1	Measurement of mesothelioma on thoracic CT scans: a comparison of manual and computer-assisted techniques. <i>Medical Physics</i> , <b>2004</b> , 31, 1105-15	4.4	60